**Biosimilars:**
Expanding Options for Patient Care

Extensive use of and growing demand for biologics come at a time when there is increasing need for savings and efficiencies for health care systems. Biosimilars are highly similar in terms of safety and effectiveness to an existing biologic medicine, with no clinically meaningful differences.

Biosimilars are much more complex than small molecules and are created in living systems that require significant expertise and state-of-the-art technology.

Biosimilars are evaluated in rigorous analytical, nonclinical, and clinical studies to be licensed by the FDA.

Biosimilars may offer additional treatment options that may increase savings and efficiencies to health care systems and expand the use of biologic therapies, which may lead to better overall health outcomes.

Pfizer Biosimilars expands Pfizer’s commitment to provide therapies that may improve the lives of patients, leveraging our global presence and expertise to deliver high-quality biosimilars.

For more information, please visit PfizerBiosimilars.com.
References


